Patents by Inventor Elisabeth Defossa

Elisabeth Defossa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF
    Publication number: 20240109882
    Abstract: The present disclosure relates to isoxazolidines and their use as receptor-interacting protein kinase 1 inhibitors, for example in the treatment of diseases and disorders mediated by RIP kinase 1.
    Type: Application
    Filed: August 8, 2023
    Publication date: April 4, 2024
    Inventors: Elisabeth DEFOSSA, Uwe HEINELT, Hans MATTER, Maria MENDEZ-PEREZ, Nils RACKELMANN, Kurt RITTER, Hauke SZILLAT, Gernot ZECH
  • Isoxazolidines as RIPK1 inhibitors and use thereof
    Patent number: 11897876
    Abstract: The present disclosure relates to isoxazolidines and their use as receptor-interacting protein kinase 1 inhibitors, for example in the treatment of diseases and disorders mediated by RIP kinase 1.
    Type: Grant
    Filed: November 9, 2022
    Date of Patent: February 13, 2024
    Assignee: GENZYME CORPORATION
    Inventors: Elisabeth Defossa, Uwe Heinelt, Hans Matter, Maria Mendez-Perez, Nils Rackelmann, Kurt Ritter, Hauke Szillat, Gernot Zech
  • ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF
    Publication number: 20230219937
    Abstract: The present invention relates to isoxazolidines of formula I and their use as receptor-interacting protein kinase 1 inhibitors, for example in the treatment of diseases and disorders mediated by RIP kinase (1) such as rheumatoid arthritis (RA), psoriasis, inflammatory bowel disease (IBD), Crohn’s disease or ulcerative colitis.
    Type: Application
    Filed: June 1, 2021
    Publication date: July 13, 2023
    Inventors: Elisabeth DEFOSSA, Heiner GLOMBIK, Uwe HEINELT, Hans MATTER, Maria MENDEZ-PEREZ, Nils RACKELMANN, Kurt RITTER, Lothar SCHWINK, Hauke SZILLAT, Gernot ZECH
  • ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF
    Publication number: 20230203027
    Abstract: The present disclosure relates to isoxazolidines and their use as receptor-interacting protein kinase 1 inhibitors, for example in the treatment of diseases and disorders mediated by RIP kinase 1.
    Type: Application
    Filed: November 9, 2022
    Publication date: June 29, 2023
    Inventors: Elisabeth DEFOSSA, Uwe HEINELT, Hans MATTER, Maria MENDEZ-PEREZ, Nils RACKELMANN, Kurt RITTER, Hauke SZILLAT, Gernot ZECH
  • NOVEL CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN
    Publication number: 20210170033
    Abstract: The invention describes novel conjugates of formula (I) of a pharmaceutical agent and a moiety capable of binding to a glucose sensing protein allowing a reversible release of the pharmaceutical agent depending on the glucose concentration.
    Type: Application
    Filed: November 30, 2018
    Publication date: June 10, 2021
    Inventors: Stefan PETRY, Elisabeth DEFOSSA, Michael PODESCHWA, Volker DERDAU, Hans MATTER, Nis HALLAND, Kaihui HU HE, Matthias DREYER, Maximilian BIELOHUBY, Melissa BESENIUS, Meltsje DE HOOP
  • Benzoimidazole-carboxylic acid amide derivatives as APJ receptor modulators
    Patent number: 9156796
    Abstract: The present invention relates to benzoimidazole-carboxylic acid amide compounds of the formula I, in which R?, R?, R??, R1, R2, R3, R4, R5, R6 and Z are defined as indicated below. The compounds of the formula I are APJ receptor modulators, and are useful for the treatment of diseases associated with increased blood pressure for example. The invention furthermore relates to the use of compounds of the formula I, in particular as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.
    Type: Grant
    Filed: September 19, 2013
    Date of Patent: October 13, 2015
    Assignee: SANOFI
    Inventors: Stephanie Hachtel, Paulus Wohlfart, John Weston, Marco Mueller, Elisabeth Defossa, Katharina Mertsch, Jian-Hui Weng, Robert Alan Binnie, Farid Abdul-Latif, William Jerome Bock, Armin Walser
  • Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
    Patent number: 8859494
    Abstract: The invention relates to spirocyclically substituted 1,3-propane dioxide derivatives, and to the physiologically compatible salts thereof. The invention relates to compounds of the formula I in which R1, R2, R3, R4, R5, R6, R7, R8, A and X are each defined as specified, and the physiologically compatible salts thereof. The compounds are suitable, for example, for treatment of diabetes.
    Type: Grant
    Filed: July 5, 2011
    Date of Patent: October 14, 2014
    Assignee: Sanofi
    Inventors: Stefanie Keil, Elisabeth Defossa, Viktoria Dietrich, Siegfried Stengelin, Andreas Herling, Guido Haschke, Thomas Klabunde
  • Phenylamino-benzoxazole substituted carboxylic acids, method for their production and use thereof as medicaments
    Patent number: 8748465
    Abstract: This invention relates to a compound of formula I, wherein R1, R2, R6, R7, R8, R9, R10, m and X are as defined herein, or a physiologically tolerated salt thereof, its pharmaceutical composition and use for lowering blood glucose, treating diabetes, or increasing insulin release.
    Type: Grant
    Filed: July 10, 2013
    Date of Patent: June 10, 2014
    Assignee: Sanofi
    Inventors: Elisabeth Defossa, Markus Follmann, Thomas Klabunde, Viktoria Dietrich, Gerhard Hessler, Siegfried Stengelin, Guido Haschke, Andreas Herling, Stefan Bartoschek
  • BENZOIMIDAZOLE-CARBOXYLIC ACID AMIDE DERIVATIVES AS APJ RECEPTOR MODULATORS
    Publication number: 20140094450
    Abstract: The present invention relates to benzoimidazole-carboxylic acid amide compounds of the formula I, in which R?, R?, R??, R1, R2, R3, R4, R5, R6 and Z are defined as indicated below. The compounds of the formula I are APJ receptor modulators, and are useful for the treatment of diseases associated with increased blood pressure for example. The invention furthermore relates to the use of compounds of the formula I, in particular as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.
    Type: Application
    Filed: September 19, 2013
    Publication date: April 3, 2014
    Applicant: SANOFI
    Inventors: Stephanie HACHTEL, Paulus WOHLFART, John WESTON, Marco MUELLER, Elisabeth DEFOSSA, Katharina MERTSCH, Jian-Hui WENG, Robert Alan BINNIE, Farid ABDUL-LATIF, William Jerome BOCK, Armin WALSER
  • (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
    Patent number: 8648038
    Abstract: The invention relates to substituted (2-aryloxyacetylamino)phenylpropionic acid derivatives, and to the physiologically acceptable salts thereof. The invention relates to compounds of the formula I in which R1, R2, R3, R4, R5, R6, R7, R8, R9 and A are each defined as specified, and the physiologically compatible salts thereof. The compounds are suitable, for example, for treatment of diabetes.
    Type: Grant
    Filed: July 5, 2011
    Date of Patent: February 11, 2014
    Assignee: Sanofi
    Inventors: Elisabeth Defossa, Stefanie Keil, Viktoria Dietrich, Siegfried Stengelin, Andreas Herling, Guido Haschke, Thomas Klabunde
  • PHENYLAMINO-BENZOXAZOLE SUBSTITUTED CARBOXYLIC ACIDS, METHOD FOR THEIR PRODUCTION AND USE THEREOF AS MEDICAMENTS
    Publication number: 20130303578
    Abstract: This invention relates to a compound of formula I, wherein R1, R2, R6, R7, R8, R9, R10, m and X are as defined herein, or a physiologically tolerated salt thereof, its pharmaceutical composition and use for lowering blood glucose, treating diabetes, or increasing insulin release.
    Type: Application
    Filed: July 10, 2013
    Publication date: November 14, 2013
    Inventors: Elisabeth DEFOSSA, Markus FOLLMANN, Thomas KLABUNDE, Viktoria DIETRICH, Gerhard HESSLER, Siegfried STENGELIN, Guido HASCHKE, Andreas HERLING, Stefan BARTOSCHEK
  • Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
    Patent number: 8530413
    Abstract: Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments The invention relates to heterocyclically substituted methoxyphenyl derivatives with an oxo group, and to physiologically compatible salts thereof. The invention relates to compounds of the formula I in which R1, R2, R3, R4, R10, X, n, B1, B2, B3 and B4 are each defined as specified, and to the physiologically compatible salts thereof. The compounds are suitable, for example, for treatment of diabetes.
    Type: Grant
    Filed: June 7, 2011
    Date of Patent: September 10, 2013
    Assignee: Sanofi
    Inventors: Stefanie Keil, Elisabeth Defossa, Viktoria Dietrich, Siegfried Stengelin, Andreas Herling, Guido Haschke, Thomas Klabunde
  • (CARBOXYLALKYLENEPHENYL)PHENYLOXAMIDES, METHOD FOR THE PRODUCTION THEREOF AND USE OF SAME AS A MEDICAMENT
    Publication number: 20130231388
    Abstract: The invention relates to (carboxylalkylenephenyl)phenyloxamides and their physiologically tolerated salts, and their use as a medicament.
    Type: Application
    Filed: April 17, 2013
    Publication date: September 5, 2013
    Applicant: SANOFI
    Inventors: Elisabeth DEFOSSA, Thomas KLABUNDE, Viktoria DIETRICH, Siegfried STENGELIN, Guido HASCHKE, Andreas HERLING, Johanna KUHLMANN-GOTTKE, Stefan BARTOSCHEK
  • (Carboxylalkylenephenyl)phenyloxamides, method for the production thereof and use of same as a medicament
    Patent number: 8518875
    Abstract: The invention relates to (carboxylalkylenephenyl)phenyloxamides and their physiologically tolerated salts, and their use as a medicament.
    Type: Grant
    Filed: March 16, 2010
    Date of Patent: August 27, 2013
    Assignee: SANOFI
    Inventors: Elisabeth Defossa, Thomas Klabunde, Viktoria Dietrich, Siegfried Stengelin, Guido Haschke, Andreas Herling, Johanna Kuhlmann-Gottke, Stefan Bartoschek
  • CXCR2 inhibitors
    Patent number: 8501981
    Abstract: The invention relates to compounds of the formula I in which R1, R2, X, A, B, Z and Y1 to Y4 have the meanings indicated in the claims, and/or a pharmaceutically acceptable salt and/or a prodrug thereof. Because of their properties as inhibitors of chemokine receptors, especially as CXCR2 inhibitors, the compounds of the formula I and the pharmaceutically acceptable salts and prodrugs thereof are suitable for the prevention and treatment of chemokine mediated diseases.
    Type: Grant
    Filed: December 17, 2008
    Date of Patent: August 6, 2013
    Assignee: SANOFI
    Inventors: Stephanie Hachtel, Juergen Dedio, Elisabeth DeFossa, Sven Grueneberg, Holger Heitsch, William Bock, Charlie Chen, Raymond Kosley, Chung-Yi Kung, Marcel Patek, Rosy Sher, Stephen Shimshock, Aleksandra Weichsel
  • 3-[4-(PHENYLAMINOOXALYLAMINO)PHENYL]HEX-4-YNOIC ACIDS, PROCESS FOR PREPARATION THEREOF AND USE THEREOF AS A MEDICAMENT
    Publication number: 20130172248
    Abstract: The invention relates to 3-[4-(phenylaminooxalylamino)phenyl]hex-4-ynoic acids, and to physiologically compatible salts thereof. The invention relates to compounds of the formula I in which R1, R2, R3 and R4 are each defined as specified, and to physiologically compatible salts thereof. The compounds are suitable, for example, for treatment of diabetes.
    Type: Application
    Filed: January 4, 2013
    Publication date: July 4, 2013
    Inventors: Elisabeth DEFOSSA, Viktoria DIETRICH, Thomas KLABUNDE, Stefanie KEIL, Siegfried STENGELIN, Guido HASCHKE, Andreas HERLING, Johanna KUHLMANN-GOTTKE, Stefan BARTOSCHEK, Simon GESSLER, Angela DUDDA, Guenter BILLEN, Thomas OLPP, Joerg RIEKE-ZAPP
  • Urea- and urethane-substituted acylureas, process for their preparation and their use
    Patent number: 8247452
    Abstract: The invention relates to urea- and urethane-substituted acylureas and to their physiologically tolerated salts and physiologically functional derivatives. In particular, the invention relates to the compounds of the formula I wherein the radicals have meanings described herein, and to their physiologically tolerated salts and to processes for their preparation. The compounds are suitable for example as antidiabetics.
    Type: Grant
    Filed: August 27, 2007
    Date of Patent: August 21, 2012
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Elisabeth DeFossa, Dieter Kadereit, Thomas Klabunde, Hans-Joerg Burger, Andreas Herling, Karl-Ulrich Wendt, Erich Von Roedern, Karl Schoenafinger
  • Substituted 8-aminoalkylthioxanthines, and their use as inhibitors of dipeptidyl peptidase IV
    Patent number: 8236810
    Abstract: The invention 8-aminothioxanthines and the derivatives of formula I wherein the various R groups and substituents are comprised of a number of different (C1-C10)-alkyl, cycloalkyl, aryl, alkene, alkyne, etc. groups and derivatives thereof which are hereinafter more specifically defined for the treatment of metabolic disorders such as type-2 diabetes, hyperglycemia, arteriosclerotic diseases and the like.
    Type: Grant
    Filed: January 11, 2007
    Date of Patent: August 7, 2012
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Karl Schoenafinger, Gerhard Jaehne, Elisabeth Defossa, Guenter Billen, Christian Buning, Georg Tschank, Ulrich Werner
  • Phenothiazine derivative having a double bond, method for the production thereof, and use thereof as a pharmaceutical
    Patent number: 8207146
    Abstract: The present invention relates to substituted phenothiazines with a double bond and physiologically acceptable salts thereof, and their use as a medicament.
    Type: Grant
    Filed: March 16, 2010
    Date of Patent: June 26, 2012
    Assignee: Sanofi-Aventis
    Inventors: Stefanie Keil, Elisabeth Defossa, Dieter Schmoll, Axel Dietrich, Johanna Kuhlmann-Gottke, Karl-Christian Engel
  • Amide-substituted 8-N-benzimidazoles, method for the production thereof, and use of the same as medicaments
    Patent number: 8163774
    Abstract: The present invention comprises the use of amino-substituted 8-N-benzimidazoles compounds of formula I wherein R3, R4-R5, R11 and R20-R21 are hereinafter defined which display a therapeutically utilizable blood sugar-lowering action. These compounds are intended to be particularly suitable in the treatment of diabetes.
    Type: Grant
    Filed: September 13, 2007
    Date of Patent: April 24, 2012
    Assignee: Sanofi-Aventis
    Inventors: Elisabeth DeFossa, Karl Schoenafinger, Gerhard Jaehne, Christian Buning, Georg Tschank, Ulrich Werner